Dec. 28, 2018 Price forecast | 2 weeks: -0.07% | 1 month: 0.22% | 3 months: 1.38%

ACOR stock forecast

Our latest prediction for Acorda Therapeutics, Inc.'s stock price was made on the Dec. 28, 2018 when the stock price was at 14.98$.

In the short term (2weeks), ACOR's stock price should underperform the market by -0.07%. During that period the price should oscillate between -9.45% and +10.85%.

In the medium term (3months), ACOR's stock price should outperform the market by 1.38%. During that period the price should oscillate between -20.26% and +28.12%.

Create a solid portfolio with ACOR

Add ACOR to your portfolio and optimize it!

About Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include AMPYRA (dalfampridine), INBRIJA (levodopa inhalation powder), BTT1023 (timolumab), SYN120, rHIgM22, and GGF2 (Cimaglermin alfa). The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

At the moment the company generates 591M USD in revenues.

On its last earning announcement, the company reported a loss of -3.21$ per share.

The book value per share is 12.78$

Acorda Therapeutics, Inc. website

Three months stock forecastDec. 28, 2018


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
591M 78.30% 168M 28.40% -147M -3.21 - - 47M 12.78 223M -27M 196M